ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Policy

Bill to Give FDA Broad New Powers

September 24, 2007 | APPEARED IN VOLUME 85, ISSUE 39

On Sept. 19, the House passed legislation that would give FDA broad new powers to monitor prescription drugs and medical devices. The bill, H.R. 3580, would increase prescription-drug user fees—the fees manufacturers pay FDA for review of their drugs-from $305 million to $392 million collected annually and devote a larger portion of the fees to postmarket safety. It would also strengthen FDA's ability to monitor and remedy false and misleading television ads for drugs and toughen labeling requirements to ensure that labels reflect study results in a timely and consistent fashion. In addition, the legislation would create a public, searchable database of clinical trials for drugs and medical devices to be administered by NIH. With the exception of preliminary studies, all trials would have to be registered. The bill is a compromise between House and Senate versions passed earlier this year and is expected to pass quickly in the Senate.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment